At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 547 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Evaluate the Overall Effect of Solifenacin 5mg and 10mg on Bladder Wall Thickness and Urinary Nerve Growth Factor in Female Subjects With Overactive Bladder and a Diagnosis of Detrusor Overactivity - A Double-blind, Randomised, Placebo-controlled, Parallel Group, Multi-centre Study.
In Brief
A Phase 4 clinical trial evaluating Placebo and solifenacin for Detrusor Overactivity and Overactive Bladder. Completed, enrolled 547 participants across 79 sites in 20 countries.
Detailed Summary
The purpose is to see if solifenacin has any effect on bladder wall thickness and urine inflammatory marker measurements after 12 weeks of treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDetrusor Overactivity, Overactive Bladder
CountriesAustria, Belgium, Bulgaria, Canada, Czechia, France, Germany, Hungary, Israel, Italy, Norway, Poland, Romania, Russia, Slovakia, Spain, Sweden, Turkey (Türkiye), United Kingdom, United States
Collaborators--
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2010
First PostedMar 2010
Primary CompletionJun 2011
TodayJul 2026
First PostedMar 26, 2010
Enrollment StartJan 19, 2010
Primary CompletionJun 23, 2011
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 16.3 years ago
Interventions
Placebodrug
Matching solifenacin placebo tablet
solifenacindrug
Tablet for oral administration